)
Abbott Laboratories (ABT) investor relations material
Abbott Laboratories M&A Announcement summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Deal rationale and strategic fit
Acquisition expands presence into advanced cancer diagnostics, addressing a major global health need with 20 million annual diagnoses worldwide.
Positions buyer at the forefront of diagnostics, expanding into preventative, predictive, and personalized cancer diagnostics, and combining complementary strengths to accelerate innovation.
Expands total addressable market to over $120 billion, doubling the opportunity and adding a new high-growth vertical.
Access to a large, underpenetrated global market and robust innovation pipeline, including liquid biopsy and blood-based cancer screening.
Focus on building the premier cancer diagnostics company, with strong positions in screening, therapy selection, and recurrence monitoring.
Financial terms and conditions
Purchase price of $105 per share in cash, total equity value of $21 billion, enterprise value of $23 billion.
Transaction unanimously approved by both boards and expected to close in Q2 2026, subject to regulatory and shareholder approvals.
Financed through a mix of cash and debt; post-close gross debt-to-EBITDA ratio projected at 2.7x.
Buyer will absorb Exact Sciences' estimated $1.8 billion net debt.
Expected to be dilutive to adjusted EPS by $0.20 in 2026 and $0.16 in 2027, accretive thereafter.
Synergies and expected cost savings
At least $100 million in annual pre-tax synergies expected by 2028, mainly from operational efficiencies.
Revenue synergies prioritized over cost-cutting; focus on sustaining high growth and leveraging global infrastructure.
Acquisition expected to be immediately accretive to revenue growth and gross margin.
Combined diagnostics sales projected to exceed $12 billion annually post-transaction.
Next Abbott Laboratories earnings date
Next Abbott Laboratories earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
The Business of Life
Abbott Laboratories is an American global and multinational healthcare company headquartered in Chicago, Illinois, and listed on the NYSE. The company is focused on manufacturing various medical devices and medications. Its products include diagnostics equipment, medical devices, nutritionals, and branded generic pharmaceuticals. Some of Abotts more well-known products include Pedialyte and FreeStyle, the latter being a monitoring system for people living with diabetes.
Sprung from a small Pharmacy
The inception of Abbott Laboratories can be traced back to 1888 when Dr. Wallace C. Abbott founded it in Chicago. Initially operating as a small pharmacy, Dr. Abbott's business focused on creating standardized drug dosages, known as "dosimetric granules", of commonly used medications. Over the decades, the company underwent significant expansion in terms of its product range and geographical outreach, transforming from its humble beginnings into a notable player in the global pharmaceutical industry.
What They Do
Abbott Laboratories offers a wide array of products and services within healthcare and nutrition. In diagnostics, it supplies tools and tests to medical facilities used in the identification of different illnesses. The company's medical devices segment manufactures equipment used in areas like cardiology, diabetes care, and neuromodulation. Additionally, they also manufacture and sell branded generic pharmaceuticals that can be purchased over the counter at pharmacies like CVS. Their portfolio of nutritional products includes products aimed both at infants and small kids, as well as adults.
Abbott Laboratories and AbbVie
In 2013, Abbott Laboratories underwent a significant transformation by spinning off its research-based pharmaceuticals division into a separate company: AbbVie. This strategic decision was aimed at allowing both companies to focus more distinctly on their respective sectors. While Abbott Laboratories retained its portfolio including medical devices, diagnostics, and nutrition, AbbVie took over the responsibility for the research-driven pharmaceutical business. This split allowed Abbott to concentrate on its extensive range of products and services, whereas AbbVie could focus on the development and commercialization of advanced therapies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage